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Chronic Obstructive Pulmonary Disease (COPD) is a debilitating and degenerative
lung disease characterized by progressive airway obstruction and alveolar destruction. When
asthma and COPD co-occur and interact, with asthma having been diagnosed first, the resulting
respiratory disease is called Asthma-COPD Overlap Syndrome (ACOS). Current research
suggests that persons with ACOS may have more severe respiratory disease and lifestyle
limitations than those with either disease alone. The purpose of the current study was to
determine if and how disease progression differs in patients with ACOS versus COPD only,
using data collected during the COPDGene cohort study. Demographic characteristics and
disease outcome measures were compared at baseline and five-year follow-up for patients with
ACOS versus COPD only. Changes in these metrics were compared using multiple linear
regression and multinomial logistic regression models controlling for BMI, pack-years of
smoking, gender, race, age, and current smoking status. The prevalence of ACOS in the current
study population was 8.5%. Overall, subjects with ACOS were younger, had less pack-years
of smoking, were more likely to be female, and were more likely to be of non-white race

compared with subjects with COPD only. Subjects with ACOS had lower quality of life scores,
larger bronchodilator responses and forced vital capacities, less emphysema, and were more
likely to experience severe COPD exacerbations at both study visits. However, changes in
disease outcomes over a five-year period were very similar between the two groups, with the
exception of frequent exacerbation status and bronchodilator response (BDR) status. Subjects
with ACOS were less likely to experience frequent COPD exacerbations, and also less likely
to display a bronchodilator response after the follow-up period, compared with subjects with
COPD alone. The reduction of frequent COPD exacerbations in patients with ACOS suggests
that treatment strategies currently used to treat asthma may have a positive effect on COPD,
while the reduction in the frequency of BDRs in these patients suggests that understanding the
inflammatory response in ACOS and preventing the associated airway remodeling may be
important topics for future research.
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BACKGROUND
Literature Review
Industrialization during the 19th and early 20th centuries has been associated with what
has come to be known as the epidemiologic transition.1 According to this model, lifestyle
changes associated with industrialization and associated better standards of living, including
improved nutrition and hygiene, have been accompanied by a shift in morbidity and
mortality.1,2 This shift is characterized by a transition from mortality among the young from
acute, often infectious, conditions to morbidity and mortality primarily among the elderly from
chronic, largely “man-made” conditions.1,2 Prior research has associated these chronic
conditions with lifestyle factors such as smoking, exposure to environmental pollution, and
sedentary habits.1,3,4 It should be noted, however, that this transition is neither complete nor
static. As evidenced by the current COVID-19 epidemic, infectious conditions are still
associated with a large burden of mortality, even in developed regions. Another notable
example of this phenomenon is the resurgence of measles in Western countries, where this
disease had been eradicated, due to a rise in anti-vaccine sentiment.5 Nevertheless, with a
growing- and aging- global population concentrated in areas that are experiencing increased
industrialization, the burden of chronic diseases is still expected to increase substantially in the
decades to come.6

Chronic obstructive pulmonary disease (COPD) is one such disease with a large, and
increasing, global disease burden.6,7 COPD is a debilitating and degenerative disease
i

characterized by progressive airway obstruction and alveolar destruction.7,8 Localized and
systemic inflammation interact in COPD, leading to fibrosis and loss of elasticity in the lung
parenchyma, which in turn leads to irreversible small airway collapse and gas trapping.8 A
reversible, cholinergic airway narrowing is also frequently seen.8 COPD has been recognized
by the World Health Organization as part of the global epidemic of noncommunicable
diseases.9 COPD has no cure, and current treatment options are limited even where there is
advanced healthcare infrastructure.6,9 In resource poor regions, COPD often goes
unrecognized, and treatment is not available.10 Prevention of COPD is mainly focused on
smoking cessation or avoidance, as well as reducing the need for burning biomass fuels and
reduction of other airborne pollutants through improving community infrastructure.9

Asthma is another chronic respiratory disease characterized by inflammation and
obstruction of the airways, although the pathophysiology of asthma is better understood than
that of COPD.8 Most cases of asthma display an allergic pattern of inflammation resulting in
airway narrowing and hyperresponsiveness, although different subtypes of disease are
increasingly being recognized.8 Like COPD, asthma has no cure, but there are effective
treatments for asthmatics- namely inhaled corticosteroids.8 Although the potential underlying
mechanism is not understood, previous diagnosis with asthma is strikingly common among
people diagnosed with COPD.11–13 For example, Soriano et al. reported 43.2% of incident
COPD cases from a study in the United Kingdom also had a previous diagnosis of asthma.12
When the two conditions co-occur and interact, with asthma having been diagnosed first, the
resulting respiratory disease is called Asthma-COPD Overlap Syndrome (ACOS).13–15
2

ACOS is increasingly being recognized as a distinct clinical phenotype with features
of both asthma and COPD.8,14,15 Current research suggests that patients with ACOS tend to
have more severe respiratory dysfunction than those with either COPD or asthma alone.8,16–18
Using cross-sectional and longitudinal analyses, Park et al. compared patients with ACOS to
patients with asthma only in a Korean cohort.18 The authors found that patients with ACOS
were older, more likely to be male, less likely to have atopy, had lower baseline lung function
with greater airway obstruction, and lower pre- and post- bronchodilator FEV1/FVC compared
to patients with asthma only.18 ACOS patients also had greater variation in FEV1 over time, a
higher rate of exacerbations during follow-up, and a larger decline in pulmonary function after
one and three years.18 These results suggest that ACOS is phenotypically distinct from asthma,
and causes a larger degree of respiratory decline over time than asthma alone.18 However, this
study did not compare ACOS to COPD alone.

Hardin et al. conducted a cross-sectional study comparing American patients with
ACOS to those with COPD alone.13 They found patients with ACOS were younger, smoked
less, were more likely to report a history of hay fever, more likely to be African American,
more likely to have had two or more COPD exacerbations in the previous year, and it was more
likely that these exacerbations were severe than in patients with COPD alone.13 The authors
also reported that patients with ACOS had increased severity of disease and worse healthrelated quality of life scores, even after adjustment for potential confounding factors.13 Direct
measures of lung function, however, were similar in the two groups.13 The authors suggested
3

that these observations may indicate that airway inflammation, rather than parenchymal
destruction, could explain the differences in disease severity and health-related quality of life
in ACOS vs COPD only subjects within this cohort.13

Public Health Significance
Global prevalence of COPD is currently estimated at 328 million people, with 168
million men and 160 million women affected, although this estimate is certain to be an
underestimate due to underdiagnosis, especially in low- and middle-income countries.6,10 By
2030, COPD is expected to directly account for 7.8% of all deaths, and 27% of smoking-related
deaths, making it the third leading cause of death globally, after cancer (33%) and
cardiovascular disease (29%).6,9 Given the tremendous burden and economic impact of COPD,
understanding and mitigating disease development and progression represents an important
public health concern.7,9,17

The economic and social burden of COPD is directly associated with several factors
including disease severity, frequency of exacerbations, and presence of comorbiditiesincluding asthma.11 As mentioned previously, asthma is a frequent comorbid condition in
patients with COPD, and patients with ACOS may have worse outcomes.11,16,17 Historically,
however, these patients have been excluded from COPD-targeted studies due to concern that
disease etiology or presentation may be different in this population, particularly as a result of
previous inhaled corticosteroid use.8,16,17,19 In studies where dual diagnosis has been allowed,
comorbid asthma was associated with poor outcomes and increased healthcare utilization using
4

cross-sectional analyses.13,16–18 However, an understanding of disease progression using
longitudinal approaches is still needed to determine how asthma and COPD interact to produce
a distinct clinical phenotype that may have unique treatment needs.18

Specific Aims
The aim of this study was to investigate how disease progression differed in patients
with ACOS compared to COPD only. This aim was focused on understanding how measures
of lung function and respiratory health changed in the five years between baseline and followup in the two patient subgroups. The rationale for this investigation was that understanding
how COPD progresses in different patient populations could inform healthcare needs and
treatment strategies. The hypothesis for this study was that patients with ACOS would have
greater COPD progression in terms of reduced lung function and worse measures of respiratory
health than patients with COPD only.

METHODS
Study Design
This study represents a secondary data analysis of data collected during the first two
phases of the Genetic Epidemiology of COPD Study. The Genetic Epidemiology of COPD
Study (COPDGene) is a multi-site observational, longitudinal cohort study investigating the
underlying genetic factors that are associated with COPD development and progression.7,20
COPDGene has enrolled over 10,000 participants since beginning in 2007 and is expected to
complete the ten-year follow-up phase of data collection in 2022.7,20 Participants in the original
5

COPDGene study were non-Hispanic whites (66.5%) and African-Americans (33.5%) aged 45
to 80 years (mean 59.5) with a history of smoking (at least 10 pack-years), with (36.2%) or
without (63.8%) a diagnosis of COPD at baseline.7 Healthy never-smokers were also included
as controls.20 Both men (53.5%) and women (46.5%) were included.7 Current smoking was
reported by 53.1% of participants, and use of supplemental oxygen was reported by 11.5% of
participants.7 At baseline and follow-up, participants completed comprehensive symptom and
comorbidity questionnaires, lung spirometry measurements, chest computed tomography (CT)
scans, and provided samples for genetic and biomarker profiling.7,20 The COPDGene study
also collected data on patient demographics, medical history, lifestyle factors, and healthcare
utilization, with the goal of developing a phenotype for patients with COPD.7,20 COPDGene is
currently in the third phase of the study, following up with patients ten years after their initial
study visit.7,20

For the current study, the first two study phases (i.e., baseline and five year follow-up)
were included for analysis as these data are the most complete.7 The COPDGene data set used
for the current study consisted of 16,482 observations, representing 10,198 individual
participants. After excluding individuals without COPD, as indicated by a baseline GOLD
score of less than two (n=6,437), (or with missing baseline GOLD scores, n=66) 3,695
participants remained in the study population.13,17 At the time of the current study, 2,099
individuals had completed the 5-year follow-up visit, leaving 1,596 individuals lost to follow
up. Using the ACOS definition described below, 314 (8.5%) individuals in the baseline study
population were identified as having ACOS, while the remaining 3,381 individuals had COPD
6

only. Of those individuals with completed follow-up visits, 182 had ACOS and 1,917 had
COPD only. A schematic view of the study population is presented in Figure 1 below.

Figure 1: Schematic view of the study population.
COPDGene
database
10,198 participants
Exclude
participants
missing baseline
GOLD score: -66
(0.65%)

10,132 (99.4%)
remaining

3,695 (36.2%)
included in
current analysis

Exclude
participants
without COPD
(GOLD Score <2):
-6,437 (63.1%)

3,381 (91.5%)
COPD only

314 (8.5%) ACOS

182 (58%)
completed

132 (42%) lost to
follow up

1,917 (56.7%)
completed

1,464 (43.3%) lost
to follow up

Asthma-COPD Overlap Syndrome
The first step of the current study was to identify the subset of patients in the
COPDGene cohort that had ACOS. This study used the ACOS definition proposed by Sin et
al (see Figure 2 for a visual depiction of this definition).14 Previous studies of ACOS have
largely been limited to using either self-reported asthma diagnosis or documentation of a
physician’s diagnosis of asthma as the only criterion for determining ACOS.11,17–19 Therefore,
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using Sin et al.’s new consensus definition in this study represents a novel and objective
strategy for identifying patients with ACOS in the COPDGene cohort study data.

This definition requires that a patient be over 40 years of age, have a post
bronchodilator forced expiratory volume to forced vital capacity ratio (FEV1/FVC) less than
0.70 or the lower limit of normal (LLN), have an exposure to tobacco or environmental
pollution greater than or equal to ten pack years of cigarette smoking, and documentation of
asthma before the age of 40 or a bronchodilator response greater than 400mL in FEV1. 14 In
addition to these “major” criteria, at least one of the following “minor” criteria must also be
present for a patient to be considered as having ACOS: documentation of allergic rhinitis or
another atopic disease, two or more instances of having a bronchodilator response of at least
200mL and 12% of baseline, or having peripheral eosinophil counts of at least 300 cells per
microliter.14 Because presence of ACOS was not directly assessed during the COPDGene
study, this information was abstracted from the clinical data that was collected in order to
determine the ACOS status of each subject.

To achieve the classification of ACOS using the COPDGene data, three new ACOS
indicator variables were created and initially given a value of “missing” for each subject. These
variables were used to track the presence of the “major” and “minor” ACOS criteria as
described above, and to assign the final ACOS classification. All participants enrolled in the
COPDGene study were between the ages of 45 and 80 at the time of enrollment, thus the first
criterion was met for all subjects. Age of subjects was determined by the difference of the date
8

of enrollment and the subject’s date of birth, and recorded in years. Any subject with an age
less than 40 was assigned a value of “0” for the ACOS indicator variable. Pre- and postbronchodilator spirometry was performed on each participant at each study visit using a
standardized study protocol and equipment20. Spirometry measurements including the
FEV1/FVC ratio and the calculated LLN were recorded as part of this study data. For subjects
with a recorded FEV1/FVC ratio less than 0.70, or below the LLN for the subject, a value of
“1” was given to the ACOS major criteria score. For subjects not meeting these spirometry
measurements, a value of “0” was assigned. Subjects documented to have at least ten pack
years of cigarette smoking, were given an additional “1” to the ACOS major criteria score, and
a “0” otherwise. Lastly, a final “1” was added to the ACOS major criteria score if
documentation of asthma before the age of 40 or a bronchodilator response greater than 400mL
in FEV1 was present for each subject. Bronchodilator response was directly measured as part
of the standardized spirometry assessment, while documentation of asthma was self-reported
in the Respiratory Disease Questionnaire completed by each subject.20 Similarly, the ACOS
“minor” criteria score was assessed by assigning a score of “1” for the presence of each
criterion, and a “0” for its absence. Documentation of allergic rhinitis or atopic disease was
self-reported in the Respiratory Disease Questionnaire.20 Instances of having a bronchodilator
response of at least 200mL and 12% of baseline were assessed as part of the spirometry, and
peripheral eosinophil counts were measured on the blood sample obtained at each study visit.20
Thus, each subject was assigned a final classification of ACOS if the major criteria score was
four points, and the minor criteria score was at least one point. Presence of ACOS was coded
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as a “1” in the indicator variable, and absence was coded as a “0”. All subjects had sufficient
exposure data to make an ACOS determination.

Major Criteria
(must have all)

Minor Criteria
(must have one)

Age ≥ 40 years

documentation
allergic rhinitis or
atopic disease

post
bronchodilator
FEV1/FVC < 0.70
or LLN

BDR ≥200 mL and
12% from baseline

≥10 pack-years
smoking history

peripheral serum
eosinophil counts
≥300 cells/µL

diagnosis of
asthma before age
40 or BDR >400 mL
in FEV1

Figure 2: Diagnostic criteria for ACOS (LLN: lower limit of normal; FEV1: forced expiratory
volume in one second; FVC: forced vital capacity; BDR: bronchodilator response)

Outcome Measures
There were ten outcome measures that were used to determine disease progression: the
body-mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index, the
Global Initiative for Obstructive Lung Disease (GOLD) score, the St. George’s Respiratory
Questionnaire (SGRQ) score, self-reported health status, the presence and severity of COPD
exacerbations, distance walked during a standard six-minute walk test, lung spirometry results,
10

and CT based measures of emphysema, airway wall thickness, and gas trapping. These indices
will be described in turn below and are summarized in Table 1.

The BODE index is a multidimensional grading system used to predict the risk of death
from any cause and the risk of death from respiratory causes in subjects with COPD. 21 This
index is calculated using a point-value system based on a subject’s FEV1(% of predicted),
distance walked in a standard six-minute walk test, score on the Medical Research Council
dyspnea scale (self-reported assessment of breathlessness), and body-mass index (BMI).21 The
BODE index ranges from zero to ten, with higher scores indicating a greater risk of death.21 In
the original cohort used to develop the BODE index, the hazard ratio for all-cause mortality
was 1.34 per one-point increase in BODE index, and the hazard ratio for respiratory diseaserelated mortality was 1.62 per one-point increase.21 The BODE index has since been validated
in several studies, and was found to be more accurate at predicting death and reduced quality
of life in COPD patients than its component measurements alone.22,23 Furthermore, these
studies indicated that a change in the BODE index can be used to track progress associated
with disease treatment.22 In the COPDGene study, data collected from the clinical examination
and patient questionnaires completed at each study visit were used to calculate the BODE score
for each participant at each visit. This score was reported as an integer between one and ten.
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Table 1: Description of outcomes and scoring systems used in the COPDGene study.
Respiratory Outcome or Score
BODE index

Description
1-10, higher score means more airway
limitation
GOLD 0
“Control” FEV1 ≥ 80%, FEV1/FVC ≥ 0.7
GOLD 1
FEV1 ≥ 80% and FEV1/FVC < 0.7
GOLD 2
50% ≤ FEV1 < 80% and FEV1/FVC < 0.7
GOLD 3
30% ≤ FEV1 < 50% and FEV1/FVC < 0.7
GOLD 4
FEV1 < 30% and FEV1/FVC < 0.7
GOLD -1
“PRISm” Preserved Ratio, Impaired
Spirometry
St. George’s Respiratory Questionnaire 0-100, Higher scores mean lower quality of
(SGRQ)
life
Self-reported general health question 1: Poor, 2: Fair, 3: Good, 4: Very Good, 5:
(SRGHQ)
Excellent; self-reported overall health
Frequent Exacerbations
0: less than two exacerbations per year
1: two or more exacerbations per year
Severe Exacerbations
0: no severe exacerbations reported
1: severe exacerbations reported
Forced expiratory volume in 1 second Amount of air, in liters, exhaled in one
(FEV1)
second
Forced vital capacity (FVC)
Maximum total amount of air exhaled, in
liters
FEV1/FVC
FEV1 to FVC ratio, normal range: 0.7-0.8
6-Minute Walk Test
Distance (in feet) walked during
standardized 6-minute walk test
Percent emphysema (-950 Hu)
CT-quantified emphysema distribution
Percent Gas Trapping (-856 Hu)
CT- quantified gas trapping distribution
Pi10 SRWA
CT- quantified airway wall thickness, square
root of wall area of a 10mm (luminal
perimeter) airway
CT: Computed Tomography; BODE: body-mass index, airflow obstruction, dyspnea, and
exercise capacity; GOLD: global initiative for obstructive lung disease; Pi10 SRWA: 10mm
luminal perimeter, square root wall area; Hu: Hounsfield units
12

The GOLD score is another multidimensional grading system used to categorize
disease severity in COPD.24 The original GOLD scoring system uses an A-B-C-D based
ranking that considers symptom severity and exacerbation history of a patient to determine
their COPD stage.24 The COPD Foundation produced a modified version of the GOLD scoring
system, which uses spirometry measurements to track disease progression. The COPD
Foundation GOLD score ranges from negative one to four, with higher scores indicating more
severe respiratory impairment.20 This modified GOLD scoring system was used during the
COPDGene study.20 As of 2011, the GOLD Foundation has also switched to this numeric
scoring system based on airflow limitation as measured by spirometry.25 The alphabetic
scoring system is still used to assess symptom severity, due to a lack of correlation between
the spirometry assessment and patient health status.25,26 Overall, the modified system appears
to be as valid as the original, but it may still need refinement (AUC 0.623 vs 0.634,
respectively).26–28

St. George’s Respiratory Questionnaire (SGRQ) is a survey style questionnaire widely
used to evaluate quality of life in individuals with COPD and other airway diseases.29 SGRQ
scores range from zero to 100, with higher scores indicating worse quality of life.29 Like the
BODE index, the SGRQ allows for comparison of scores before and after initiation of a
treatment regimen, or other follow-up period.30 The SGRQ has been validated for use in both
adults (18+) and older adults (65+) with obstructive airway disease (including COPD in
particular), making it well suited to this cohort.31–33 The test-retest intraclass correlations for
the SGRQ-B (American version) were 0.795 to 0.900.33
13

During the COPDGene study, participants were also asked to rate their overall health
(In general, how would you describe your health?) on a scale of one to five, with five meaning
they felt they were in excellent health and one meaning they felt they were in poor health.20
Participant responses are referred to as the self-reported general health question (SRGHQ)
throughout the current study. The question was asked without a reference period, and thus may
be subject to recall bias. However, other studies have found that this type of question can still
be valid in a variety of contexts, thus it was chosen that the question should remain in the
current analysis.34

The presence and severity of COPD exacerbations was assessed as follows.
COPDGene participants were recorded as having frequent COPD exacerbations if they
reported having at least two exacerbations in the previous year.17,20 A dichotomous indicator
variable was created and given a value of “1” if the participant reported two or more COPD
exacerbations on the Respiratory Disease Questionnaire and a “0” otherwise. Similarly,
presence of severe exacerbations was concluded if participants reported having a respiratory
complication that resulted in a hospital or emergency department visit.17,20 This response was
coded in a second indicator variable, using a “1” to indicate an emergency department visit
and a “0” otherwise, again using the participant response from the Respiratory Disease
Questionnaire.
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As mentioned previously, pre- and post-bronchodilator pulmonary function testing was
completed in compliance with the American Thoracic Society guidelines, using a standardized
study protocol and spirometer.20,35 Forced expiratory volume in one second (FEV1) and forced
vital capacity (FVC) were recorded in liters, and the FEV1/FVC ratio was recorded as a
decimal. ATS guidelines were also followed in the administration of the standardized sixminute walk test.20,36 Results of the six-minute walk test (distance walked) were recorded in
feet. Computed tomography (CT) scans were used to compute the percent area of the lung with
tissue densities indicative of emphysematous changes or gas trapping (density thresholds of 950 and -856 Hounsfield units, respectively).37 CT scans were also used to calculate airway
wall thickness by measuring the square root of the wall area of small airways (airways with a
10mm luminal perimeter). Greater values of this metric have previously been associated with
increased levels of airway disease.37 Detailed protocols for these assessments, as well as the
protocol for the acquisition of CT scans can be found in the study protocol appendices linked
in Reagan EA, Hokanson JE, Murphy JR, et al. 2010.20

Covariates
Covariates included factors that have already been associated with worse outcomes in
COPD: age, gender, race, BMI, and pack-years of smoking.17 Older patients with COPD (65+)
have demonstrated worse lung function and exercise tolerance, as well as increased frequency
of comorbidities when compared to younger patients in previous studies.7 Female sex has also
previously been associated with higher disease severity, independently of other relevant
factors.7 Racial differences in COPD outcomes have also been found, with African American
15

subjects experiencing lower quality of life scores during COPD exacerbations and
hospitalizations as compared to non-Hispanic Whites.7 Adjusting for pack-years of smoking
allows the current analysis to evaluate the effects of asthma on COPD progression
independently of potential differences in exposure to tobacco products. Lastly, BMI has been
associated with reduced 6-minute walk test performance and greater dyspnea, independently
of COPD status, so the current analysis needs to take measures to reduce the potential effect
of obesity on ACOS related outcomes.7

Study Power
The COPDGene study contains records for over 10,000 participants. According to the
study by Hardin et al.17 using preliminary baseline data from the COPDGene cohort, of 915
subjects with COPD, 119 were identified as having comorbid asthma and 796 subjects had
COPD only. As reported in the results section below, the current study identified 3,695 subjects
with COPD only and 314 subjects with ACOS. Of these subjects, 1,917 and 182 completed the
five year follow up study, respectively. Focusing the power analysis on the SGRQ score, as
this measure has had the minimal meaningful difference determined and validated38, we see
that patients with COPD alone had an average change in SGRQ score of 1.77±15.75 points,
while patients with ACOS had an average change in SGRQ score of -1.57±15.94 points
(p=0.009, Table 5, below). Using the population sizes at follow-up, an alpha level of 0.05,
setting the effect size to the minimal meaningful difference of 4 points, and the student’s t test
for two independent sample means, this study had a power of 0.77 to detect this difference.
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Thus, we may anticipate that the current study was adequately powered to detect meaningful
differences.

Data Analysis
Subjects that participated in both study visits were included in the final (change values
and multivariable) analysis. For the cross-sectional comparisons, subjects who were lost to
follow up were included to allow for the comparison of the lost cohort to the retained cohort.
For the cross-sectional analyses, missing values for individual outcome measures were allowed
at each timepoint. However, for the longitudinal analysis, only subjects with complete data at
both visits were included. Markers of disease outcomes for COPD vs ACOS subjects were
compared at baseline and follow-up using descriptive statistics (mean ± standard deviation,
median ± interquartile range, mode, and range as appropriate). Chi-squared tests were used to
detect differences in categorical variables, which included BODE index, GOLD score, selfreported health status, smoking status, presence of severe exacerbations, presence of frequent
exacerbations, and bronchodilator response, between the two groups at baseline and followup. Independent samples T-tests were used to detect differences among the continuous
variables, which included BMI, pack years of smoking, SGRQ score, six-minute walk test,
forced vital capacity- percent predicted, forced expiratory volume -percent predicted, volume
of bronchodilator response as a percent of FEV1, percent gas trapping on CT, percent
emphysema on CT, and airway wall thickness, between the two groups at baseline and followup. For all statistical tests, p-values of ≤ 0.05 were considered significant differences.
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To account for the correlation of outcomes between phase 1 and phase 2, and to adjust
for other covariates, the multiple linear regression for continuous outcomes (e.g. SGRQ score,
six-minute walk test results, and CT-derived measures of emphysema and airway wall
thickness), or the multinomial logistic regression model for categorical outcomes (e.g.,
presence of a bronchodilator response, presence of frequent exacerbations, presence of severe
exacerbations, and BODE index) was used to compare ACOS versus COPD only patients.
These models were applied to change variables representing the difference in disease outcomes
between baseline and follow-up measurements. Categorical change variables were coded as
“increased,” “decreased,” or “no change” for variables representing scores (ex. BODE and
GOLD scores), and “developed,” “lost,” or “no change” for variables representing the presence
or absence of a condition (ex. BDR, severe exacerbations, frequent exacerbations). For
example, if a participant reported the presence of severe exacerbations at baseline, but reported
the absence of severe exacerbations at follow-up, the change variable for severe exacerbations
would be coded as “lost” for this participant. By contrast, if a participant did not have a BDR
at baseline, but did have a BDR at follow-up, the change variable for BDR would be coded as
“developed” for this participant. Multiple regression model assumptions were checked using
the Breusch-Pagan test for heteroskedasticity, Shapiro-Wilk’s test for normality of residuals,
variance inflation factors for multicollinearity, the link test to check for model specification
problems, the Ramsey Regression Equation Specification Error Test to check for the use of an
appropriate functional form, and Cook’s distance to check for influential points. The
Independence of Irrelevant Alternatives (IIA) assumption for the multinomial logistic
regression model was checked, and the data were also checked for case specificity. All
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multivariable models were adjusted for differences in baseline outcome measures (age, gender,
race, BMI, current smoking status, and pack-years of smoking).

To investigate the potential for differential loss to follow-up, baseline characteristics of
participants who completed the five-year follow-up visit were compared to those participants
who were lost to follow-up. These data are summarized in Table 2, below. While ACOS status,
age, smoking status, and BDR (% FEV1) were similar between completers and lost
participants, differences were detected for the remaining measures. Loss to follow up was more
frequent among African Americans (20.6% vs 25.4% African Americans, Χ2(1, N=3695) =
9.64, p=0.002) and males (52.8% vs 59.0% males, Χ2(1, N=3695) = 15.68, p<0.001).
Participants who were lost to follow up also had lower BMI (mean ±SD: 28.63 ±6.14 vs 27.32
±6.40, p<0.001), greater pack-years of smoking (mean ±SD: 51.25 ±25.54 pack-years vs 55.14
±29.84 pack-years, p<0.001), higher SGRQ scores (mean ±SD: 36.39 ±21.32 points vs 46.79
±21.26 points, p<0.001), and lower self-reported general health than participants who
completed the study (31.2% vs 45.9% scored 1 or 2 points, Χ2(4, N=3693) = 153.46, p<0.001).
They also performed worse on the six-minute walk test (mean ±SD: 1263.28 ±363.15 feet vs
1052.48 ±408.70 feet, p<0.001), had lower FVC (% predicted) (mean ±SD: 79.20 ±15.98% vs
72.59 ±18.04%, p<0.001), lower FEV1 (% predicted) (mean ±SD: 54.12 ±16.30% vs 45.15
±18.80%, p<0.001), greater percent gas trapping (mean ±SD: 36.01 ±19.20% vs 42.24
±21.66%, p<0.001), greater percent emphysema (mean ±SD: 11.69 ±11.57% vs 15.60
±14.29%, p<0.001), and greater airway wall thickness than study completers (mean ±SD: 2.68
±0.56 units vs 2.84 ±0.56 units, p<0.001). Finally, participants who were lost to follow up had
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higher baseline GOLD (39.4% vs 58.5% scored 3 or 4, Χ2(2, N=3695) = 241.72, p<0.001) and
BODE (6.2% vs 20.7% scored over 5 points, Χ2(10, N=3597) = 300.56, p<0.001) scores, and
were more likely to have reported experiencing severe COPD exacerbations (19% vs 27.3%,
Χ2(1, N=3695) = 40.29, p<0.001), frequent COPD exacerbations (15.2% vs 21.7%, Χ2(1,
N=3695) = 27.71, p<0.001), and inhaled corticosteroid use (Χ2(1, N=3563) = 16.16, p<0.001)
compared to participants who were not lost to follow-up. However, loss to follow-up was
independent of ACOS status (8.7% vs 8.3%, Χ2(1, N=3695) = 0.187, p=0.666), and is thus not
expected to change the observed associations of the exposure and outcomes under
investigation.

Table 2: Demographic and health characteristics of the study cohort, complete cases versus
lost to follow up, at baseline.
Baseline (N= 3695)
Lost to Follow
Complete Cases
up
(N = 2099)
(N = 1596)

p-value*

Mean (SD)
BMI
Age at baseline
Pack years of smoking
SGRQ score (total)
6-minute walk test distance
FVC (% predicted)
FEV1 (% predicted)
BDR (% FEV1)
% Gas trapping
% Emphysema
Airway wall thickness
N (%)
ACOS (yes)
Gender (male)

28.63 (6.14)
63.16 (8.30)
51.25 (25.54)
36.39 (21.32)
1263.28 (363.15)
79.20 (15.98)
54.12 (16.30)
9.04 (12.72)
36.01 (19.20)
11.69 (11.57)
2.68 (0.56)

27.32 (6.40)
63.52 (8.83)
55.14 (29.84)
46.79 (21.26)
1052.48 (408.70)
72.59 (18.04)
45.15 (18.80)
8.70 (13.90)
42.24 (21.66)
15.60 (14.29)
2.84 (0.56)

<0.001
0.208
<0.001
<0.001
<0.001
<0.001
<0.001
0.439
<0.001
<0.001
<0.001

182 (8.7%)
1107 (52.7%)

132 (8.3%)
946 (59.3%)

0.666
<0.001
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Race (Caucasian)
1661 (79.1%)
1194 (74.8%)
0.002
SRGH score 1
102 (4.9%)
197 (12.3%)
<0.001
2
555 (26.5%)
540 (33.8%)
3
886 (42.3%)
644 (40.4%)
4
475 (22.7%)
189 (11.8%)
5
79 (3.8%)
26 (1.6%)
Smoking status (current)
1266 (60.3%)
925 (58.0%)
0.149
GOLD score 2
1265 (60.3%)
660 (41.4%)
<0.001
3
653 (31.1%)
511 (32.0%)
4
181 (8.6%)
425 (26.6%)
BODE score 0
390 (18.8%)
142 (9.3%)
<0.001
1
353 (17.1%)
173 (11.3%)
2
370 (17.9%)
174 (11.4%)
3
339 (16.4%)
221 (14.5%)
4
287 (13.9%)
239 (15.7%)
5
205 (9.9%)
253 (16.6%)
6
100 (4.8%)
229 (15.0%)
7
24 (1.2%)
72 (4.7%)
8
2 (0.1%)
14 (0.9%)
9
0 (0.0%)
8 (0.5%)
10
0 (0.0%)
2 (0.1%)
Severe Exacerbations (yes)
396 (18.9%)
442 (27.7%)
<0.001
Frequent Exacerbations (yes)
319 (15.2%)
350 (21.9%)
<0.001
Inhaled Corticosteroids (yes)
214 (10.6%)
231 (15.0%)
<0.001
*p-value for completed vs lost, t-test (means) or chi-square test (proportions)
BMI: body-mass index; SGRQ: Saint George’s respiratory questionnaire; FVC:
forced vital capacity; FEV1: Forced expiratory volume in one second; BDR:
bronchodilator response; SRGH: self-reported general health; GOLD: global
initiative for obstructive lung disease; BODE: body-mass index, airflow
obstruction, dyspnea, and exercise capacity

Data Handling and Informed Consent
All study data are previously collected data from an IRB approved study (UTHSCSA
protocol number HSC20070644H). Written informed consent was obtained from all
participants before study initiation. Additional UTHealth Committee for the Protection of
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Human Subjects (CPHS) approval for this project was also obtained (protocol number HSCSPH-20-0850). These data do not contain any personally identifying health information, as
they have been stripped of all personal identifiers as defined by the UTHealth CPHS and
UTHSCSA Institutional Review Board. Nevertheless, study data was transferred to the student
using a password protected, fully encrypted USB drive and stored on a password protected,
secure computer. All study data stored by the student was destroyed upon completion of the
current project.

RESULTS
Cross-Sectional Analyses
Table 3, below, contains the demographic and health status information for the study
population at baseline. Compared to participants with COPD only, patients with ACOS were
younger (mean ±SD: 63.56 ±8.44 years vs 60.66 ±9.13 years, respectively p<0.001), more
likely to be female (56.3% vs 47.8% males, Χ2(1, N=3695) = 8.44, p=0.004), less likely to be
Caucasian (78.1% vs 68.5% Caucasian, Χ2(1, N=3695) = 15.11, p<0.001), and smoked less
(mean ±SD: 53.39 ±27.49 pack-years vs 47.98 ±27.71 pack-years, respectively p=0.001).
Participants with ACOS also scored higher on the SGRQ (mean ±SD: 40.36 ±21.90 points vs
46.52 ±21.25 points, p<0.001), and reported lower self-perceived general health than
participants with COPD only (37.1% vs 44.6% scored 1 or 2 points, Χ2(4, N=3693) = 10.98,
p=0.027). Several measures of pulmonary structure and function were also different between
the two groups, with participants with ACOS having higher FVC (% predicted) (mean ±SD:
76.07 ±17.17% vs 79.33 ±17.43%, p=0.001), higher BDR (% FEV1) (mean ±SD: 8.31
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±12.64% vs 15.07 ±17.30%, p<0.001), greater airway wall thickness (mean ±SD: 2.73 ±0.56
units vs 2.92 ±0.64 units, p<0.001), and less percent emphysema (mean ±SD: 13.60 ±13.09%
vs 10.58 ±10.74%, p<0.001). Lastly, participants with ACOS were more likely to report
experiencing severe COPD exacerbations (21.9% vs 30.6%, Χ2(1, N=3695) = 12.19, p<0.001)
and more likely to report experiencing frequent COPD exacerbations (16.9% vs 30.6%, Χ2(1,
N=3695) = 35.98, p<0.001) than participants with COPD only. Participants with ACOS tended
to report inhaled corticosteroid use more frequently and current smoking less frequently than
participants with COPD only, but these trends did not reach statistical significance. Baseline
BMI, GOLD scores, BODE scores, 6-minute walk test results, FEV1 (% predicted), and
percent gas trapping on CT scans were all similar between the two groups.

Table 3: Demographic and health characteristics of the study cohort at baseline.
Baseline (N= 3695)
COPD only
ACOS
(N = 3381)
(N = 314)

p-value*

Mean (SD)
BMI
Age (in years)
Pack years of smoking
SGRQ score (total)
6-minute walk test distance
FVC (% predicted)
FEV1 (% predicted)
BDR (% FEV1)
% Gas trapping
% Emphysema
Airway wall thickness
N (%)
Gender (male)
Race (Caucasian)

28.01 (6.25)
63.56 (8.44)
53.39 (27.49)
40.36 (21.90)
1171.28 (397.62)
76.07 (17.17)
50.15 (18.07)
8.31 (12.64)
38.70 (20.56)
13.60 (13.09)
2.73 (0.56)

28.62 (6.70)
60.66 (9.13)
47.98 (27.71)
46.52 (21.25)
1200.83 (390.07)
79.33 (17.43)
51.26 (16.94)
15.07 (17.30)
37.36 (19.66)
10.58 (10.74)
2.92 (0.64)

0.101
<0.001
0.001
<0.001
0.213
0.001
0.296
<0.001
0.316
<0.001
<0.001

1903 (56.3%)
2640 (78.1%)

150 (47.8%)
215 (68.5%)

0.004
<0.001
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SRGH score 1
268 (7.9%)
31 (9.9%)
0.027
2
986 (29.2%)
109 (34.7%)
3
1403 (41.5%)
127 (40.4%)
4
626 (18.5%)
38 (12.1%)
5
96 (2.8%)
9 (2.9%)
Smoking status (current)
2019 (59.7%)
172 (54.8%)
0.088
GOLD score 2
1753 (51.8%)
172 (54.8%)
0.367
3
1065 (31.5%)
99 (31.5%)
4
563 (16.7%)
43 (13.7%)
BODE score 0
498 (15.1%)
34 (11.1%)
0.274
1
484 (14.7%)
42 (13.7%)
2
487 (14.8%)
57 (18.6%)
3
507 (15.4%)
53 (17.3%)
4
485 (14.7%)
41 (13.4%)
5
411 (12.5%)
47 (15.4%)
6
308 (9.4%)
21 (6.9%)
7
86 (2.6%)
10 (3.3%)
8
15 (0.5%)
1 (0.3%)
9
8 (0.2%)
0 (0.0%)
10
2 (0.1%)
0 (0.0%)
Severe Exacerbations (yes)
742 (21.9%)
96 (30.6%)
<0.001
Frequent Exacerbations (yes)
573 (16.9%)
96 (30.6%)
<0.001
Inhaled Corticosteroids (yes)
397 (12.2%)
48 (16.0%)
0.055
*p-value for COPD only vs ACOS, t-test (means) or chi-square test (proportions)
BMI: body-mass index; SGRQ: Saint George’s respiratory questionnaire; FVC:
forced vital capacity; FEV1: Forced expiratory volume in one second; BDR:
bronchodilator response; SRGH: self-reported general health; GOLD: global
initiative for obstructive lung disease; BODE: body-mass index, airflow
obstruction, dyspnea, and exercise capacity

Similarly, univariate demographic and health status information for study participants
at the 5-year follow-up visit is summarized below in Table 4. At follow-up, participants with
ACOS were again younger (mean ±SD: 69.04 ±8.25 years vs 66.16 ±8.52 years, respectively
p<0.001), more likely to be female (53.6% vs 43.4% males, Χ2(1, N=2099) = 6.96, p=0.008),
less likely to be Caucasian (79.8% vs 72.5% Caucasian, Χ2(1, N=2099) = 5.27, p=0.022), and
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smoked less (mean ±SD: 53.00 ±25.87 pack-years vs 47.18 ±24.42 pack-years, p=0.004) than
participants with COPD only. Participants with ACOS again scored higher on the SGRQ than
participants with COPD only (mean ±SD: 36.88 ±21.01 points vs 40.84 ±21.85 points,
p=0.021) but self-reported general health was similar between the two groups (unlike at
baseline). As with the baseline visit, measures of pulmonary structure and function were also
different between the two groups at follow-up, with participants with ACOS having higher
FVC (% predicted) (mean ±SD: 75.30 ±16.89% vs 78.39 ±17.37%, p=0.028), higher BDR (%
FEV1) (mean ±SD: 9.15 ±11.04% vs 12.77 ±13.60%, p<0.001), greater airway wall thickness
(mean ±SD: 2.68 ±0.55 units vs 2.85 ±0.62 units, p<0.001), and less percent emphysema (mean
±SD: 12.90 ±12.89% vs 10.56 ±11.09%, p=0.034). At follow-up, participants with ACOS were
still more likely to report experiencing severe COPD exacerbations than participants with
COPD only (19.4% vs 28.7%, Χ2(1, N=2080) = 8.85, p=0.003), but the two groups were
equally likely to report experiencing frequent COPD exacerbations, making this the only other
measurement (along with SRGH score) that changed in terms of the presence of a statistically
significant difference between baseline and follow-up. Inhaled corticosteroid use, smoking
status, BMI, GOLD scores, BODE scores, 6-minute walk test results, FEV1 (% predicted), and
percent gas trapping on CT scans were all similar between the two groups at follow-up, just as
they were at baseline. A summary of these demographic and health characteristics at baseline
using only the follow-up cohort (n=2,099) is included in the appendices.

Table 4: Demographic and health characteristics of the study cohort at follow-up.
Follow-up (N= 2099)
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COPD only
(N = 1917)

ACOS
(N = 182)

28.12 (6.37)
69.04 (8.25)
53.00 (25.87)
36.88 (21.01)
1094.14 (432.65)
75.30 (16.89)
51.71 (18.76)
9.15 (11.04)
38.70 (20.41)
12.90 (12.89)
2.68 (0.55)

28.92 (6.93)
66.16 (8.52)
47.18 (24.42)
40.84 (21.85)
1146.54 (420.43)
78.39 (17.37)
53.09 (17.64)
12.77 (13.60)
36.06 (20.68)
10.56 (11.09)
2.85 (0.62)

0.130
<0.001
0.004
0.021
0.149
0.028
0.374
<0.001
0.153
0.034
<0.001

1028 (53.6%)
1529 (79.8%)
113 (6.7%)
466 (27.4%)
755 (44.5%)
302 (17.8%)
62 (3.7%)
1351 (71.1%)
686 (42.6%)
515 (32.0%)
227 (14.1%)
277 (18.0%)
253 (16.4%)
281 (18.2%)
235 (15.2%)
230 (14.9%)
165 (10.7%)
69 (4.5%)
26 (1.7%)
7 (0.5%)
369 (19.4%)
273 (14.2%)
147 (8.0%)

79 (43.4%)
132 (72.5%)
10 (6.0%)
60 (35.9%)
68 (40.7%)
24 (14.4%)
5 (3.0%)
124 (68.5%)
72 (45.3%)
49 (30.8%)
18 (11.3%)
28 (18.8%)
17 (11.4%)
26 (17.4%)
26 (17.4%)
27 (18.1%)
21 (14.1%)
2 (1.3%)
1 (0.7%)
1 (0.7%)
52 (28.7%)
29 (15.9%)
17 (9.7%)

0.008
0.022
0.226

p-value*

Mean (SD)
BMI
Age (in years)
Pack years of smoking
SGRQ score (total)
6-minute walk test distance
FVC (% predicted)
FEV1 (% predicted)
BDR (% FEV1)
% Gas trapping
% Emphysema
Airway wall thickness
N (%)
Gender (male)
Race (Caucasian)
SRGH score 1
2
3
4
5
Smoking status (current)
GOLD score 2
3
4
BODE score 0
1
2
3
4
5
6
7
8
Severe Exacerbations (yes)
Frequent Exacerbations (yes)
Inhaled Corticosteroids (yes)
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0.456
0.333

0.327

0.003
0.534
0.445

*p-value for COPD only vs ACOS, t-test (means) or chi-square test (proportions)
BMI: body-mass index; SGRQ: Saint George’s respiratory questionnaire; FVC:
forced vital capacity; FEV1: Forced expiratory volume in one second; BDR:
bronchodilator response; SRGH: self-reported general health; GOLD: global
initiative for obstructive lung disease; BODE: body-mass index, airflow
obstruction, dyspnea, and exercise capacity

Longitudinal Analyses
Changes in disease progression between participants with ACOS and COPD only are
summarized in Table 5, below. Change in BMI, pack-years of smoking, six-minute walk test
results, FVC (% predicted), and FEV1 (% predicted) were similar for the two groups. CT based
measures of percent gas trapping, percent emphysema, and airway wall thickness were also
similar between participants with ACOS and COPD only. Frequency of increases or decreases
in BODE scores, GOLD scores, and self-reported general health scores were approximately
the same in participants with ACOS compared to participants with COPD only. Both groups
were also equally like to quit or re-start smoking, or to develop or lose severe COPD
exacerbations. By contrast, participants with ACOS were more likely to lose frequent COPD
exacerbations (Χ2(2, N=2099) = 26.44, p<0.001), more likely to lose a BDR (Χ2(2, N=1757)
= 28.53, p<0.001), and more likely to discontinue or initiate inhaled corticosteroid use (Χ2(2,
N=1951) = 6.36, p=0.042) than participants with COPD only. Change in BDR (% FEV1)
(mean ±SD: 0.60 ±15.42% vs -3.18 ±18.98%, p=0.004) and SGRQ scores (mean ±SD: 1.77
±15.75 vs -1.57 ±15.94, p=0.009) were also different between the two groups.

Table 5: Change in demographic characteristics of the study cohort from baseline to followup with descriptive statistics.
Follow-up (N= 2099)
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COPD Only
(N=1917)
Mean (SD)
Change in BMI
Change in pack years
Change in SGRQ score
Change in 6 min walk distance

-0.39 (3.17)
1.29 (2.31)
1.77 (15.75)
-187.11
(370.03)
-4.06 (14.12)
-3.09 (11.09)
0.60 (15.42)
3.98 (10.20)
1.75 (5.42)
0.02 (0.42)

ACOS
(N=182)
-0.36 (3.88)
1.16 (1.89)
-1.57 (15.94)
-149.35 (349.48)

p-value*
0.937
0.463
0.009
0.226

Change in FVC (% predicted)
-4.16 (14.61)
0.932
Change in FEV1 (% predicted)
-2.77 (10.37)
0.723
Change in BDR (%FEV1)
-3.18 (18.98)
0.004
Change in % gas trapping
3.96 (10.71)
0.986
Change in % emphysema
1.40 (4.92)
0.451
Change in airway wall thickness
-0.01 (0.43)
0.376
N (%)
Change in BODE score (increase)
508 (33.3%)
30 (20.1%)
0.742
(decrease)
296 (19.4%)
45 (30.2%)
Change in GOLD score (increase)
312 (19.4%)
26 (16.4%)
0.611
(decrease)
266 (16.5%)
29 (18.2%)
Change in SRGH score (increase)
505 (29.8%)
48 (28.7%)
0.922
(decrease)
325 (19.2%)
31 (18.6%)
Develop severe exacerbations
254 (13.4%)
30 (16.6%)
0.393
Lose severe exacerbations
229 (12.1%)
24 (13.3%)
Develop frequent exacerbations
185 (9.7%)
15 (8.2%)
<0.001
Lose frequent exacerbations
178 (9.3%)
39 (21.4%)
Initiate inhaled corticosteroids
93 (5.2%)
13 (7.6%)
0.042
Discontinue inhaled corticosteroids
130 (7.3%)
20 (11.7%)
Quit smoking
244 (12.8%)
25 (13.8%)
0.726
Re-start smoking
38 (2.0%)
5 (2.8%)
Develop BDR
308 (19.3%)
13 (8.2%)
<0.001
Lose BDR
328 (20.5%)
59 (37.1%)
*p-value for COPD only vs ACOS, t-test (means) or chi-square test (proportions)
BMI: body-mass index; SGRQ: Saint George’s respiratory questionnaire; FVC: forced vital
capacity; FEV1: Forced expiratory volume in one second; BDR: bronchodilator response;
SRGH: self-reported general health; GOLD: global initiative for obstructive lung disease;
BODE: body-mass index, airflow obstruction, dyspnea, and exercise capacity

As shown in Table 6, beta coefficients for ACOS were not different from zero for the
models predicting change in percent emphysema, change in percent gas trapping, change in
airway wall thickness, or change in six-minute walk test scores. However, the beta coefficient
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for ACOS in the model predicting change in SGRQ score (β coefficient (95% confidence
interval): -2.81 (-5.33, -0.282), p=0.029) was different from zero. For each model, variance
inflation factors were all less than 5.0, the link test p-value was greater than 0.05, the Ramsey
Regression Equation Specification Error Test p-value was greater than 0.05, and Cook’s
distance was less than 1.0. The Breusch-Pagan test and Shapiro-Wilk’s both rejected the null
hypothesis for each of the models tested, however when the residual plots were examined it
was determined that the rejection of these tests was likely due to the large sample size in the
study, as the plots did not display large deviations from the model assumptions.

Table 6: Beta coefficients for the effect of ACOS versus COPD only on the changes in
continuous outcomes from baseline to follow-up.
Outcome
β coefficient (95% CI)
change in % emphysema
-0.21 (-1.12, 0.71)
change in % gas trapping
-0.05 (-1.99, 1.90)
change in airway wall thickness
-0.02 (-0.01, 0.05)
change in SGRQ score
-2.81 (-5.33, -0.28)
change in 6-min walk test score
23.8 (-37.8, 85.3)
All models adjusted for the following baseline covariates: BMI,
pack-years of smoking, gender, race, age, and current smoking
status. (BMI: body-mass index; SGRQ: St. George’s respiratory
questionnaire)

As shown in Table 7 below, relative risk ratios (RRRs) for changes in BODE scores,
GOLD scores, the development or loss of severe COPD exacerbations, and the development
of frequent COPD exacerbations were not different in participants with ACOS compared to
participants with COPD only. However, the RRRs for the loss of frequent COPD exacerbations
(RRR (95% CI): 2.43 (1.63, 3.63)) and the loss (RRR= 2.00 (1.40, 2.86)) or development
(RRR= 0.47 (0.26, 0.87)) of a BDR were different in participants with ACOS compared to
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participants with COPD only. For each model, the IIA assumption was met, and the data were
determined to be case- specific, thus meeting the assumptions necessary for using the
multinomial logistic regression model.

Table 7: Relative risk ratio (RRR) estimates for the effects of ACOS versus COPD only on
the change in categorical outcomes from baseline to follow-up.
Outcome (vs no change)
RRR (95% CI)
BODE score
Decrease in BODE score
0.89 (0.57, 1.40)
Increase in BODE score
0.85 (0.57, 1.26)
GOLD score
Decrease in GOLD score
0.97 (0.63, 1.50)
Increase in GOLD score
0.82 (0.52, 1.30)
Exacerbations
Loss of frequent exacerbations
2.43 (1.63, 3.63)
Development of frequent exacerbations 0.85 (0.48, 1.49)
Loss of severe exacerbations
1.05 (0.67, 1.67)
Development of severe exacerbations
1.34 (0.88, 2.06)
BDR
Loss of BDR
2.00 (1.40, 2.86)
Development of BDR
0.47 (0.26, 0.87)
All models adjusted for the following baseline covariates: BMI,
pack-years of smoking, gender, race, age, and current smoking
status. (BMI: body-mass index; BDR: bronchodilator response;
GOLD: global initiative for obstructive lung disease; BODE:
body-mass index, airflow obstruction, dyspnea, and exercise
capacity)

DISCUSSION
The current study used data collected during the COPDGene cohort study to investigate
the presence and magnitude of differences in disease progression between subjects with ACOS
and those with COPD only. Prior research has failed to reach a consensus regarding whether
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people with ACOS represent a distinct patient subgroup, with different disease trajectories
from patients with COPD only.39,40 Overall, the current study suggested that, at a particular
point in time, subjects with ACOS do have reduced quality of life and greater evidence of
reactive airway disease compared to subjects with COPD only. However, the magnitude of
changes in disease outcomes over time were very similar between the two groups, with the
exceptions of SGRQ scores, frequent exacerbation status, and BDR status.

Rates of ACOS in the current study (using Sin et al.’s definition) were lower than those
reported in previous studies using only self-reported history of asthma to define ACOS (current
study: 8.5%, previous studies 12.6%13 - 13%17, p<0.001). However, because there is no “gold
standard” test to assess ACOS, it is impossible to say whether the current rate represents less
misclassification, or is merely different from previous studies. Subject characteristics in the
current study were consistent with previous research indicating female gender, non-Caucasian
race, lower pack-years of smoking, and younger age were significantly associated with ACOS
compared to COPD only.13,17 These subject characteristics remained consistently different
between the study groups at the five-year follow-up visit, further suggesting that a causal
mechanism may be at play. Similarly, SGRQ scores were consistently higher in subjects with
ACOS across the study timepoints, meaning that ACOS was associated with lower quality of
life throughout the five-year follow-up period. ACOS was further associated with higher FVC
(% predicted), higher BDR (% FEV1), greater airway wall thickness, and less percent
emphysema at both baseline and follow-up, suggesting that clinical parameters of airway
disease are different in these patients. Specifically, these patients appear to have both a
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restrictive and reactive lung disease rather than a purely obstructive lung disease. Not
surprisingly perhaps, subjects with ACOS were more also likely to report experiencing severe
COPD exacerbations and a history of chronic bronchitis than their COPD only counterparts at
both timepoints. This observation further enhances the idea of ACOS as a mixed phenotype of
reactive, restrictive, and obstructive airway disease that, when exacerbated, may be expected
to produce severe respiratory distress.
As mentioned previously, the primary hypothesis of the current study was that ACOS
patients would display disease progression characteristics that were distinct from patients with
COPD only. Specifically, ACOS patients were expected to have greater decreases in measures
of lung function, be more likely to develop frequent or severe COPD exacerbations, and
experience greater reductions in quality of life compared to patients with COPD only. Indeed,
the current study found that the magnitude of change in BDR (% FEV1) and SGRQ scores was
different in subjects with ACOS versus COPD only. On average, subjects with ACOS
experienced a 3.18% decrease in BDR (%FEV1), meaning that the degree of irreversible
airway limitation increased over the study period. Such progression has been associated with
increased risk of severe asthma perturbations and declines in lung function due to
inflammation- mediated structural remodeling of the airways.41

SGRQ scores for participants with ACOS declined by an average of 1.57 points, while
scores for participants with COPD alone increased by 1.77 points on average. However, as
mentioned previously, the minimum meaningful difference for the SGRQ metric is 4 points.38
Therefore, while these differences may be statistically significant, their practical significance
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may be limited. Such a difference could be explained by normal variations in SGRQ scores
across different settings. Participants with ACOS were also more likely to lose frequent COPD
exacerbations, more likely to lose a BDR, and more likely to discontinue or initiate inhaled
corticosteroid use than participants with COPD only. Similar to the observed decline in the
magnitude of patients’ BDR, the loss of a BDR entirely represents a significant advancement
of disease, as airflow limitation is no longer reversible in these patients. Changes in the use of
inhaled corticosteroids may also be indicative of increasing disease severity, as these drugs are
useful for controlling bronchial hyperreactivity and their cessation may be due to the
development of steroid resistant lung disease or comorbidities for which the use of steroids is
contraindicated.42 The significance of the loss of frequent COPD exacerbations in subjects with
ACOS is less clear. This trend does not appear to be due to differential loss to follow-up, as
subjects with ACOS who experienced frequent exacerbations at baseline were not more likely
to be lost to follow up than those who did not experience frequent exacerbations. Possibly this
effect was caused by an unmeasured confounding variable. Because the effects of potential
confounding variables cannot be accounted for using univariate methods, this trend was
investigated further in the multivariable models described below.

For the multivariable models, adjustment for covariates was done using the baseline
BMI, pack-years, gender, race, age, and smoking status. Although some authors have raised
concerns that adjustment using baseline measurements when the outcome is a change variable
may introduce bias, the current study does not meet the criteria identified by these authors as
concerning for bias.43 Furthermore, when adjustment using the change in covariates rather than
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baseline covariates was used, the estimated coefficients were nearly identical, suggesting that
bias was not a concern in this study. Therefore, the baseline measurements were used for model
adjustment, as these variables are more easily interpreted in the context of the current study
than the change measurements would have been.

In these longitudinal models, changes in SGRQ score, loss of frequent COPD
exacerbations, and the loss or development of a BDR remained significantly different between
participants with ACOS compared to participants with COPD only. Changing from COPD
only to ACOS status was associated with a 2.81-point decrease in SGRQ score, while
controlling for the mentioned covariates. While this average change is less than the minimal
important difference of four points, the 95% CI (-5.33, -0.282) includes this value, meaning
that it is plausible for ACOS to be associated with a meaningful decrease in SGRQ score. 38
However, most of the 95% CI is less than the minimal important difference, suggesting that
we should be cautious about over- interpreting the decrease in SGRQ scores observed in the
current study.

Consistent with the unadjusted model, study participants with ACOS had a relative risk
for losing frequent COPD exacerbations that was 2.43 (95% CI: 1.63, 3.63) times the relative
risk of experiencing no change in frequent exacerbations, when the covariates were included.
This consistency lends weight to the idea that there is something about having ACOS that
reduces the risk of experiencing two or more COPD exacerbations per year. Possibly it is just
differential classification of exacerbation events in these subjects as related to the patient’s
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asthma diagnosis rather than their concurrent COPD diagnosis, leading to the (incorrect)
appearance of a reduction in COPD exacerbations. However, it is also possible that one or
more of the treatments used to mitigate asthma may also be having a positive effect on COPD
severity in these patients. Indeed, current research investigating the use of anti-eosinophil
therapies (currently used to treat severe eosinophilic asthma) for the prevention of
exacerbations and mortality in patients with COPD supports this idea.8,44

Lastly, participants with ACOS were 2.00 (95% CI: 1.40, 2.86) times more likely to
experience the loss of a BDR, and 0.474 (95% CI 0.258, 0.869) times less likely to develop a
BDR during the follow up period compared to experiencing no change in their BDR status.
This is perhaps the most important finding of the current study because it suggests a trend in
patients with ACOS to become more “COPD-like” over time, lending credence to the idea that
COPD and ACOS may represent a continuous spectrum of a single disease rather than two
distinct patient subtypes.19 Persistence of airflow limitation in both ACOS and COPD patients
could be linked to structural remodeling of the lungs caused by increased activity of the
proteolytic

enzymes

known

as

matrix

metalloproteinases,

specifically

matrix

metalloproteinase 9 (MMP-9). MMP-9 has been associated with disease severity in
independent studies of patients with asthma and COPD.45–47 Thus, the MMP-9/ tissue inhibitor
of MMP (TIMP) axis may represent a future avenue of treatment that warrants further
investigation. Taken together, these data suggest that ACOS, rather than being a distinct
pathophysiological phenotype, may instead represent an imperfect proxy for an unrecognized
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underlying inflammatory response that perhaps accounts for the wide variation in symptom
severity seen in patients with COPD.

Limitations and Future Directions
The current study does have a few limitations to consider. First, to ensure enough
subjects in each category to allow race to be used as a covariate, the COPDGene study only
enrolled non-Hispanic Caucasian and African American subjects, and therefore may not be
generalizable to populations with greater racial or ethnic diversity. Future studies are thus still
needed to determine the prevalence of ACOS in populations that are more racially diverse than
the current study. Additionally, as with all longitudinal studies, this study suffered from loss
to follow-up. Comparison of participants who were lost to follow up with participants who
completed the study revealed many significant differences between these two study
populations. Specifically, participants who were lost to follow up appeared to be those most
severely affected in terms of both quality of life and symptom severity. While this phenomenon
is not uncommon in epidemiologic studies, it represents a potential source of bias and should
be acknowledged.48

Lastly, ACOS status had to be retrospectively abstracted from data that were not
collected for the purpose of making this determination. It is likely that this process resulted in
some unknown degree of misclassification, and the observed effects might have been different
if the study had used data where ACOS status was assessed directly. Direct methods of
exposure assessment are generally more reliable than indirect methods, and any improvement
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in the reliability of exposure assessment can reduce bias and improve statistical power of a
study.49 For example, if ACOS misclassification occurred due to imperfect data abstraction in
the current study, and was non-differential with respect to the outcome(s), the observed trends
will have been underestimated. Further studies using direct assessment of ACOS are still
needed to determine if such biases have clouded the current understanding of ACOS and
COPD.

In the future, it will also be important to investigate whether the observed trends are
continued long-term. Phase three of the COPDGene study (the ten-year follow-up visits) will
give us an opportunity to examine whether or not, and to what degree, the trends observed in
this study persist. Expanding on the idea of an unrecognized inflammatory perturbation
underlying COPD severity, the impact of adaptive (Th2) immunity in chronic diseases has
come under increasing scrutiny, and the contribution of such Th2- driven inflammation to
disease progression in COPD and ACOS should be investigated.4,8,50 For example, CD4+/CD8+
T-cell ratios, cytokines, and chemokines could be measured in peripheral blood and/ or
bronchoalveolar lavage fluid.51 Such studies could inform the potential use of emerging
biologic therapies to improve quality of life and reduce the burden of COPD and ACOS.52,53

CONCLUSION
The current study addressed an important gap in the literature, namely how COPD
progression differs in patients with ACOS versus COPD only. The data presented here are
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largely consistent with the previous study by Hardin et al. examining differences between
patients with ACOS versus COPD only. However, Hardin et al.’s study was only able to
include baseline data for the first 2,500 subjects enrolled in the COPDGene cohort, and defined
ACOS simply as having COPD and a prior physician’s diagnosis of asthma.13 As such, the
current study represented an innovative approach by using the new consensus definition of
ACOS and by including all patients enrolled at baseline, as well as including patients with fiveyear follow-up data. This study identified many differences in cross-sectional disease severity
between subjects with ACOS compared with COPD only. The longitudinal approaches applied
in the current study also identified a reduction of frequent COPD exacerbations in patients with
ACOS, suggesting that treatment strategies currently reserved for asthmatics may benefit those
with COPD as well, while the loss of a BDR in these patients suggests that prevention of airway
remodeling may also be an important topic for future research.
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APPENDICES
Table A.1: Demographic and health characteristics of the follow-up cohort at baseline.
Baseline (N= 2099)
COPD only
ACOS
(N = 1917)
(N = 182)

p-value*

Mean (SD)
BMI
Age (in years)
Pack years of smoking
SGRQ score (total)
6-minute walk test distance
FVC (% predicted)
FEV1 (% predicted)
BDR (% FEV1)
% Gas trapping
% Emphysema
Airway wall thickness
N (%)
Gender (male)
Race (Caucasian)
SRGH score 1
2
3
4
5
Smoking status (current)
GOLD score 2
3
4
BODE score 0
1
2
3
4
5
6

28.57 (6.11)
63.41 (8.22)
51.69 (25.50)
35.77 (21.21)
1260.10 (364.00)
78.92 (15.90)
54.05 (16.41)
8.39 (12.03)
36.10 (19.23)
11.88 (11.71)
2.66 (0.55)

29.23 (6.49)
60.52 (8.67)
46.65 (25.53)
42.99 (21.44)
1297.14 (353.23)
82.14 (16.53)
54.79 (15.12)
15.80 (17.07)
35.06 (18.90)
9.76 (9.93)
2.87 (0.66)

0.165
<0.001
0.011
<0.001
0.193
0.009
0.559
<0.001
0.522
0.020
<0.001

1028 (53.6%)
1529 (79.8%)
91 (4.8%)
494 (25.8%)
814 (42.5%)
444 (23.2%)
72 (3.8%)
1161 (60.6%)
1151 (60.0%)
597 (31.1%)
169 (8.8%)
362 (19.1%)
325 (17.2%)
331 (17.5%)
308 (16.3%)
267 (14.1%)
184 (9.7%)
93 (4.9%)

79 (43.4%)
132 (72.5%)
11 (6.0%)
61 (33.5%)
72 (39.6%)
31 (17.0%)
7 (3.8%)
105 (57.7%)
114 (62.6%)
56 (30.8%)
12 (6.6%)
28 (15.7%)
28 (15.7%)
39 (21.9%)
31 (17.4%)
20 (11.2%)
21 (11.8%)
7 (3.9%)

0.008
0.022
0.115

39

0.449
0.564

0.507

7
20 (1.1%)
4 (2.2%)
8
2 (0.1%)
0 (0.0%)
Severe Exacerbations (yes)
349 (18.2%)
47 (25.8%)
0.012
Frequent Exacerbations (yes)
266 (13.9%)
53 (29.1%)
<0.001
Inhaled Corticosteroids (yes)
191 (10.3%)
23 (13.1%)
0.055
*p-value for COPD only vs ACOS, t-test (means) or chi-square test (proportions)
BMI: body-mass index; SGRQ: Saint George’s respiratory questionnaire; FVC:
forced vital capacity; FEV1: Forced expiratory volume in one second; BDR:
bronchodilator response; SRGH: self-reported general health; GOLD: global
initiative for obstructive lung disease; BODE: body-mass index, airflow
obstruction, dyspnea, and exercise capacity
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